Quantcast

Cancer Monoclonal Antibodies Market Forecast to 2017

March 13, 2014

DUBLIN, March 13, 2014 /PRNewswire/ –

Research and Markets (
http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal) has announced the
addition of the “Cancer Monoclonal Antibodies Market Forecast to 2017″
[http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal ] report to their
offering.

(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )

Cancer, one of the leading causes of death worldwide, affected approximately 13
Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The
dramatic increase in the size of the potential cancer market has prompted pharmaceutical
players to invest in the oncology sector with major focus on monoclonal antibodies.

Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and
stimulate an immune response so are very specific to targets. Various monoclonal
antibodies for treatment of cancer are available in the market and many more are in the
pipeline. According to this report, “Cancer Monoclonal Antibodies Market Forecast to
2017″, the market for cancer mAbs is estimated at US$ 24 Billion, and is expected to grow
to around US$ 34 Billion by 2017.

The report, in particular, provides an insight to the global burden of cancer, with
detailed breakdown of incidences by type and geography. It not only estimates the current
burden but also makes future predictions. There is an exhaustive overview of the
monoclonal technology, helping the client understand the various types of antibodies and
the diverse types of cancer therapies which make use of mAbs.

In this report, the authors have profiled every anti-cancer monoclonal antibody
available in the market and estimated the current and future market of five of them. The
report covers major trends which are driving the current market and a country level
analysis of the status of cancer mAbs.

Through this pipeline analysis of the various mAbs, it has been revealed that majority
of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid
Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major
change in the market in terms of market share of current drugs.

Finally, the authors conclude its report with a competitive analysis of the major mAb
players, providing brief descriptions of every player along with a list of current and
pipeline mAbs. The report can therefore, provide assistance in evaluating the current
market, discovering potential areas and analyzing the competitive environment.

        Key Topics Covered:

        1. Analyst View

        2. Research Methodology

        3. The Global Burden of Cancer

        4. Global Cancer Market Outlook to 2017

        5. Monoclonal Antibodies: Introduction and Working

        6. Industry Trends and Drivers

        7. Global Cancer mAbs Market Outlook to 2017

        8. Pipeline Analysis of Cancer Monoclonal Antibodies

        9. Competitive Landscape

Companies Mentioned:

        - Amgen
        - Bristol-Myers Squibb
        - Eli Lilly
        - Genmab
        - GlaxoSmithKline
        - Roche
        - Seattle Genetics
        - Spectrum Pharmaceuticals

For more information visit

http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


    Photo: 

http://photos.prnewswire.com/prnh/20130307/600769

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus